Onsdag 28 Oktober | 18:57:10 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

BONESUPPORT - Solid performance in Q4, critical juncture up ahead

2022-02-18 10:00:00

Redeye notes another record quarter for BONESUPPORT and is encouraged by the persistent sales growth during a most peculiar year for elective surgeries. We reiterate our Base Case of SEK 80 and argue that the stock could soon see a fairer price closer to its peers, with a potential FDA approval as a clear trigger.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/